These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 23651186)

  • 1. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
    Vesely MD; Schreiber RD
    Ann N Y Acad Sci; 2013 May; 1284(1):1-5. PubMed ID: 23651186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
    Matsushita H; Vesely MD; Koboldt DC; Rickert CG; Uppaluri R; Magrini VJ; Arthur CD; White JM; Chen YS; Shea LK; Hundal J; Wendl MC; Demeter R; Wylie T; Allison JP; Smyth MJ; Old LJ; Mardis ER; Schreiber RD
    Nature; 2012 Feb; 482(7385):400-4. PubMed ID: 22318521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunoediting: from immunosurveillance to tumor escape.
    Dunn GP; Bruce AT; Ikeda H; Old LJ; Schreiber RD
    Nat Immunol; 2002 Nov; 3(11):991-8. PubMed ID: 12407406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
    Kunimasa K; Goto T
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of tumour-specific antigens underlies cancer immunoediting.
    DuPage M; Mazumdar C; Schmidt LM; Cheung AF; Jacks T
    Nature; 2012 Feb; 482(7385):405-9. PubMed ID: 22318517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunobiology of cancer immunosurveillance and immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Immunity; 2004 Aug; 21(2):137-48. PubMed ID: 15308095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Schreiber RD; Old LJ; Smyth MJ
    Science; 2011 Mar; 331(6024):1565-70. PubMed ID: 21436444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy.
    Baxevanis CN
    Cancer Immunol Immunother; 2019 May; 68(5):705-707. PubMed ID: 30955066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and prospects of immunotherapy as cancer treatment.
    Rescigno M; Avogadri F; Curigliano G
    Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immunoediting and immunosculpting pathways to cancer progression.
    Reiman JM; Kmieciak M; Manjili MH; Knutson KL
    Semin Cancer Biol; 2007 Aug; 17(4):275-87. PubMed ID: 17662614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy.
    Effros RB
    Cancer Immunol Immunother; 2004 Oct; 53(10):925-33. PubMed ID: 15067431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Immunoediting in the Era of Immuno-oncology.
    Gubin MM; Vesely MD
    Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural innate and adaptive immunity to cancer.
    Vesely MD; Kershaw MH; Schreiber RD; Smyth MJ
    Annu Rev Immunol; 2011; 29():235-71. PubMed ID: 21219185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The critical role of type-1 innate and acquired immunity in tumor immunotherapy.
    Ikeda H; Chamoto K; Tsuji T; Suzuki Y; Wakita D; Takeshima T; Nishimura T
    Cancer Sci; 2004 Sep; 95(9):697-703. PubMed ID: 15471553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunoediting and "spontaneous" tumor regression.
    Sengupta N; MacFie TS; MacDonald TT; Pennington D; Silver AR
    Pathol Res Pract; 2010 Jan; 206(1):1-8. PubMed ID: 19945228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
    Ward JP; Gubin MM; Schreiber RD
    Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The three Es of cancer immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse immunoediting: When immunity is edited by antigen.
    Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
    Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.